Sight Sciences, Inc. (NASDAQ: SGHT) disclosed a Form 4 filing showing that Chief Financial Officer James Rodberg sold 7,231 shares of common stock on April 6, 2026. The shares were transacted at a weighted average price of $3.55, yielding gross proceeds of $25,670.
The filing lists the range of prices for the shares sold between $3.43 and $3.58. Company filings indicate the disposition was undertaken to meet a tax liability arising from the vesting of restricted stock units.
After the sale, Rodberg's direct holdings in Sight Sciences total 230,939 shares. That figure includes shares that will be acquired upon the future vesting and settlement of restricted stock units that remain outstanding.
Market performance this year has been challenging for the stock, which is down 56% year-to-date. Over a longer horizon, the share price is up 48% relative to the same point twelve months ago. InvestingPro data cited in the disclosure shows the stock trading near a Fair Value estimate of $3.40 and describes the share price as having experienced volatile movements.
These insider disclosures come against a backdrop of recent corporate developments. Sight Sciences reported fourth-quarter 2025 results that beat consensus estimates on the earnings line. The company recorded earnings per share of -$0.08, compared with a consensus expectation of -$0.15. Revenue in the quarter was $20.4 million, slightly above the $20.17 million forecast.
In parallel to the financial results, Sight Sciences secured a significant legal outcome. The U.S. District Court for the District of Delaware affirmed a jury verdict finding that Alcon Inc. willfully infringed three of Sight Sciences' patents. The judgment awarded Sight Sciences $34 million in monetary damages, comprised of $5.5 million in lost profits and $28.5 million in royalty damages.
Following these developments, William Blair reiterated an Outperform rating on Sight Sciences. The firm cited the company's disciplined expense management as a contributor to the earnings outperformance.
Taken together, the insider sale, the recent quarterly beat, and the upheld patent verdict represent discrete corporate events disclosed within public filings and analyst commentary. The Form 4 identifies the insider sale as a tax-driven transaction related to RSU vesting and leaves Rodberg with a substantial direct ownership position in the company.